Drugs / P53-SLP vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00844506 | Oct 2008 → Jul 2009 | ovarian cancer | University Medical Center Groningen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P53-SLP vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00844506 ↗ |
| Modality | Vaccine | “The P53-SLP vaccine is a vaccine” NCT00844506 ↗ |
| Route | Subcutaneous | “Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval” NCT00844506 ↗ |